Vivos Therapeutics Future Growth
Future criteria checks 2/6
Vivos Therapeutics is forecast to grow earnings and revenue by 30.6% and 32.4% per annum respectively while EPS is expected to grow by 53% per annum.
Key information
30.6%
Earnings growth rate
52.95%
EPS growth rate
| Healthcare earnings growth | 19.7% |
| Revenue growth rate | 32.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Jul 2026 |
Recent future growth updates
Recent updates
Narrative Update • Jul 02
VVOS: Insomnia Study And New Partnerships Will Drive Future Upside
Analysts have reduced their price target on Vivos Therapeutics to $2.45 from $5.83, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Vivos Therapeutics highlights a mix of cautious and constructive views, with the lower price targets reflecting updated assumptions on discount rates, revenue growth, margins, and future P/E levels rather than a single headline issue.
Narrative Update • Jun 18
VVOS: Compliance Progress And Capital Raises Will Support Future Stock Rebound
Analysts have adjusted their price target on Vivos Therapeutics downward by several dollars to reflect revised growth expectations, updated discount rate assumptions, and a higher projected future P/E multiple, as illustrated by recent target cuts to $4.50 and $0.75. Analyst Commentary Recent research on Vivos Therapeutics highlights a more cautious tone, with bearish analysts revisiting their assumptions on growth, valuation, and execution risk.Narrative Update • Jun 03
VVOS: Nasdaq Compliance Plan And Fresh Capital Will Support Future Rebound
Narrative Update: Vivos Therapeutics Analysts have cut their price targets on Vivos Therapeutics by amounts including $4.50 and $0.75, citing updated assumptions for revenue growth, profit margin, discount rate, and future P/E that together support a refreshed fair value estimate of $1.75 per share. Analyst Commentary Recent research updates on Vivos Therapeutics point to more cautious sentiment, with analysts trimming price targets and resetting expectations around revenue growth, margins, discount rates, and future P/E assumptions.Narrative Update • May 14
VVOS: Nasdaq Compliance Plan And New Funding Will Support Future Upside Potential
Narrative Update on Vivos Therapeutics Analysts have trimmed their price targets on Vivos Therapeutics by a combined $5.25, citing updated assumptions for fair value, a higher discount rate, more moderate revenue growth, slightly higher profit margins, and a higher future P/E multiple. Analyst Commentary Recent Street research on Vivos Therapeutics points to a more cautious tone among bearish analysts, reflected in reduced price targets that incorporate updated assumptions around discount rates, revenue trajectories, margins, and valuation multiples.
Narrative Update • Apr 28
VVOS: Future Revenue Execution Could Support Rebased Bullish Outlook
Analysts have revised their fair value estimate for Vivos Therapeutics from $6.50 to $3.00, citing updated views on required discount rates, revenue growth assumptions, profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on Vivos Therapeutics has focused on recalibrating price targets to reflect updated assumptions around discount rates, revenue trajectories, profitability, and future P/E multiples.Narrative Update • Apr 12
VVOS: Expanded Sleep Apnea Study And New Funding Will Support Future Upside Potential
Analysts have nudged their price target on Vivos Therapeutics higher to $2.50 from $2.40, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These revisions modestly refine their view of the stock's risk and earnings power.Narrative Update • Mar 28
VVOS: Expanded Sleep Apnea Treatment Indications Will Support Future Upside Potential
Analysts have adjusted their price target on Vivos Therapeutics to $2.50 from $2.50. This reflects updated views on discount rates, revenue growth, profit margins and future P/E assumptions, while keeping the overall valuation level unchanged.Narrative Update • Mar 14
VVOS: Sleep Center And Digital Sleep Tools Expansion Will Support Upside Potential
Analysts held their $2.50 price target for Vivos Therapeutics, citing only slight shifts in their modeled discount rate, revenue growth, profit margin, and future P/E assumptions that together keep their overall valuation view broadly unchanged. What's in the News Filed a follow on equity offering of up to US$6 million in common stock, covering 75,000,000 shares at an indicated price of US$0.08 per share (Follow on Equity Offering).Narrative Update • Feb 27
VVOS: Sleep Center Expansion And Partnerships Will Support Future Upside Potential
Analysts have adjusted their price target for Vivos Therapeutics slightly, reflecting small shifts in discount rate, expected revenue growth, profit margin outlook, and assumed future P/E. They now view the shares as fairly valued around $2.50.Narrative Update • Feb 09
VVOS: New Sleep Center Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Vivos Therapeutics to an updated US$2.50, reflecting refreshed assumptions around discount rates, revenue growth, profit margins and forward P/E that together refine their view of the stock's risk and earnings profile. What's in the News Vivos Therapeutics entered a collaboration with SoundHealth to distribute SoundHealth's Sonu Band and Spatial Sleep band through Vivos' network of over 2,000 trained dentists, sleep healthcare providers, and affiliated sleep testing centers, with Vivos acting as a reseller across its network (Client Announcements).Narrative Update • Jan 26
VVOS: New Sleep Center And Financing Will Support Future Upside Potential
Analysts have trimmed their price target on Vivos Therapeutics to reflect a slightly higher discount rate and a modest adjustment in projected profit margins. Revenue growth assumptions and future P/E expectations remain broadly consistent, leading to a revised fair value estimate of around $2.50 per share.Narrative Update • Jan 10
VVOS: Sleep Center Affiliations Will Drive Future Upside Potential
Analysts have reduced their fair value estimate for Vivos Therapeutics from $4.00 to $2.50, citing updated assumptions that combine a higher discount rate with significantly faster modeled revenue growth, a slightly adjusted profit margin profile, and a lower future P/E multiple in their valuation analysis. What's in the News Opened a new sleep testing and treatment center near Detroit in Auburn Hills, Michigan, extending its sleep center affiliation model that already operates in Las Vegas, Nevada (Key Developments).Narrative Update • Nov 21
VVOS: Significant Clinical Findings Will Drive Upside in 2024
Analysts have raised their price target for Vivos Therapeutics from $5.10 to $5.83 per share. They cited improved revenue growth projections and modest adjustments to future profitability assumptions.Narrative Update • Aug 22
Acquisitions And Sleep Center Integrations Will Expand Future Markets
The sharp upward revision in the analyst price target for Vivos Therapeutics reflects markedly improved revenue growth forecasts and a lower future P/E multiple, raising fair value from $4.22 to $5.10. What's in the News Vivos Therapeutics will be unable to file its next 10-Q by the SEC deadline.Analysis Article • Jul 02
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected
The Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) share price has done very well over the last month, posting an excellent...
New Narrative • Apr 15
FDA Clearance And Middle East Expansion Will Secure Future Success
Strategic alliances and clinic acquisitions aim to increase patient conversions, boosting revenue and margins through higher treatment uptake.Analysis Article • Apr 05
Positive Sentiment Still Eludes Vivos Therapeutics, Inc. (NASDAQ:VVOS) Following 26% Share Price Slump
Unfortunately for some shareholders, the Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) share price has dived 26% in the last...Analysis Article • Feb 16
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have retraced a considerable 30% in the last month, reversing a fair...Analysis Article • Dec 27
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar
Despite an already strong run, Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have been powering on, with a gain of...Analysis Article • Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have continued their recent momentum with a 27% gain in the last month...Analysis Article • Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shareholders would be excited to see that the share price has had a great...Analysis Article • Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shareholders that were waiting for something to happen have been dealt a blow...Analysis Article • Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shares have retraced a considerable 48% in the last month, reversing a fair...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 34 | -14 | N/A | -30 | 3 |
| 12/31/2026 | 24 | -24 | N/A | -28 | 3 |
| 3/31/2026 | 20 | -25 | -20 | -17 | N/A |
| 12/31/2025 | 17 | -21 | -18 | -15 | N/A |
| 9/30/2025 | 17 | -17 | -15 | -14 | N/A |
| 6/30/2025 | 14 | -14 | -16 | -14 | N/A |
| 3/31/2025 | 15 | -11 | -15 | -14 | N/A |
| 12/31/2024 | 15 | -11 | -13 | -13 | N/A |
| 9/30/2024 | 15 | -13 | -13 | -12 | N/A |
| 6/30/2024 | 14 | -12 | -12 | -11 | N/A |
| 3/31/2024 | 13 | -16 | -12 | -11 | N/A |
| 12/31/2023 | 14 | -14 | -13 | -12 | N/A |
| 9/30/2023 | 15 | -15 | -13 | -12 | N/A |
| 6/30/2023 | 15 | -19 | -16 | -15 | N/A |
| 3/31/2023 | 16 | -20 | -18 | -17 | N/A |
| 12/31/2022 | 16 | -24 | -21 | -20 | N/A |
| 9/30/2022 | 16 | -25 | -22 | -21 | N/A |
| 6/30/2022 | 17 | -25 | -20 | -19 | N/A |
| 3/31/2022 | 17 | -22 | -20 | -18 | N/A |
| 12/31/2021 | 17 | -20 | -18 | -16 | N/A |
| 9/30/2021 | 16 | -24 | -17 | -15 | N/A |
| 6/30/2021 | 15 | -21 | -14 | -12 | N/A |
| 3/31/2021 | 13 | -19 | -9 | -9 | N/A |
| 12/31/2020 | 13 | -18 | -6 | -6 | N/A |
| 9/30/2020 | 13 | -9 | -4 | -4 | N/A |
| 6/30/2020 | 13 | -11 | -4 | -4 | N/A |
| 3/31/2020 | 12 | -12 | -4 | -4 | N/A |
| 12/31/2019 | 11 | -12 | N/A | -5 | N/A |
| 12/31/2018 | 4 | -9 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VVOS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VVOS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VVOS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VVOS's revenue (32.4% per year) is forecast to grow faster than the US market (13% per year).
High Growth Revenue: VVOS's revenue (32.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VVOS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 14:46 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vivos Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Lucas Ward | Ascendiant Capital Markets LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |